Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First IL-6-blocking drug nears approval for rare blood disorder.

Literature DB >> 24100967

First IL-6-blocking drug nears approval for rare blood disorder.

Sarah C P Williams.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 24100967 DOI： 10.1038/nm1013-1193

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

1 in total

1. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Authors: Razelle Kurzrock; Peter M Voorhees; Corey Casper; Richard R Furman; Luis Fayad; Sagar Lonial; Hossein Borghaei; Sundar Jagannath; Lubomir Sokol; Saad Z Usmani; Helgi van de Velde; Xiang Qin; Thomas A Puchalski; Brett Hall; Manjula Reddy; Ming Qi; Frits van Rhee
Journal: Clin Cancer Res Date: 2013-05-09 Impact factor: 12.531

1 in total

8 in total

1. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.

Authors: Joong-Jae Lee; Hyun Jung Kim; Chul-Su Yang; Hyun-Ho Kyeong; Jung-Min Choi; Da-Eun Hwang; Jae-Min Yuk; Keunwan Park; Yu Jung Kim; Seung-Goo Lee; Dongsup Kim; Eun-Kyeong Jo; Hae-Kap Cheong; Hak-Sung Kim
Journal: Mol Ther Date: 2014-03-31 Impact factor: 11.454

Review 2. Hallmarks of Bone Metastasis.

Authors: Rachelle W Johnson; Larry J Suva
Journal: Calcif Tissue Int Date: 2017-11-14 Impact factor: 4.333

8. Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.

Authors: Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal: Clin Case Rep Date: 2018-02-21

8 in total

First IL-6-blocking drug nears approval for rare blood disorder.

1. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

1. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.

Review 2. Hallmarks of Bone Metastasis.

3. Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.

Review 4. KSHV targeted therapy: an update on inhibitors of viral lytic replication.

5. Endothelial lipase is upregulated by interleukin-6 partly via the p38 MAPK and p65 NF-κB signaling pathways.

Review 6. Integrating Interleukin-6 into depression diagnosis and treatment.

Review 7. Contribution of the KSHV and EBV lytic cycles to tumourigenesis.

8. Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.